Navigation Links
New study identifies novel role for PEA-15 protein in cancer growth
Date:11/21/2011

HONOLULUA new study from the University of Hawaii Cancer Center reveals that PEA-15, a protein previously shown to slow ovarian tumor growth and metastasis, can alternatively enhance tumor formation in kidney cells carrying a mutation in a cancer-promoting gene called H-Ras.

The H-Ras oncogene is mutated in many human malignancies, and previous reports have shown the ability of H-Ras to contribute to the development, proliferation and metastasis of these tumors. Conversely, PEA-15 had been reported to inhibit tumor cell proliferation and metastasis by opposing H-Ras signals. In ovarian and breast cancer, PEA-15 is proposed to have promising therapeutic potential and in ovarian cancer PEA-15 has shown promise as a marker of prolonged patient survival.

This new study is the first finding of a pro-cancer effect of PEA-15 on proliferation and as such suggests caution in pursuing the use of PEA-15 as an anti-cancer therapeutic. The study results were published online today in the journal Oncogene.

"Our findings reveal a surprising mechanism by which PEA-15 can enhance H-Ras driven transformation of cells, rather than stop it," said Joe W. Ramos, Ph.D., associate professor at the University of Hawaii Cancer Center and co-director of its Cancer Biology Program. "We showed that in a common scenario in which a cell contains a Ras mutation, PEA-15 can accelerate the rate of tumor formation both in vitro and in vivo," he added.

In contrast to reports suggesting a tumor-suppressor function of PEA-15, Ramos said the discovery confirms that PEA 15 expression can also trigger tumor growth. "What we now know is that PEA-15 can either enhance or impair the formation of tumors depending on the signaling pathways active in a specific tumor cell."

"As with most cancers, an interplay of factors determines the fate of a patient," noted Florian Sulzmaier, a researcher at the UH Cancer Center and first author of the newly published study. "PEA-15 might still be worth considering for treatment of certain cancers. However, care should be taken in tumor types that carry Ras mutations that could change the outcome of a therapy."


'/>"/>

Contact: Kellie Tormey
ktormey@cc.hawaii.edu
808-564-5814
University of Hawaii Cancer Center
Source:Eurekalert

Related biology news :

1. UT Dallas research widens study of brains role in tinnitus
2. Study of flower petals shows evolution at the cellular level
3. Study explains how heart attack can lead to heart rupture
4. Study details links between climate, groundwater availability - will help states prepare for drought
5. Long-term study shows acid pollution in rain decreased with emissions
6. New study links excessive amounts of vitamin D to onset of atrial fibrillation
7. Study IDs new genetic links to impulsivity, alcohol problems in men
8. Forests cooler or warmer than open areas depending on latitude, study finds
9. Harm not those strangers that pollinate, study warns
10. MSU researcher sent to Siberia to study global change
11. Trees adapt to poor levels of sunlight to effectively process carbon, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
(Date:2/2/2016)... VIEW, Calif. , Feb. 2, 2016 /PRNewswire/ ... retinopathy market, Frost & Sullivan recognizes US-based Intelligent ... America Frost & Sullivan Award for New Product ... provider in North America , ... in the rapidly growing diabetic retinopathy market. The ...
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. a ... West Chester, Ohio announced today ... service staff, based in Austin, Texas ... ability to provide modifications, installations and technical support offerings ... CEO of PLUS, commented, "PLUS has provided world class ...
Breaking Biology News(10 mins):
(Date:2/3/2016)... , Feb. 3, 2016   ViaCyte, Inc ... the first pluripotent stem cell-derived islet replacement therapy ... clinical-stage development, today announced that ViaCyte and Janssen ... of Johnson & Johnson, have agreed to consolidate ... ViaCyte.  The agreement provides ViaCyte with an exclusive ...
(Date:2/3/2016)... Denmark , Feb. 3, 2016 Ascendis ... biotechnology company that applies its innovative TransCon technology to ... present at an upcoming investor conference.Event:2016 Leerink Partners Global ... NY Date:  , Wednesday, February 10, 2016 Time:  ... www.ascendispharma.com . --> An audio webcast ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a ... dedicated to the North American healthcare market. , Aerocom Healthcare, LLC will be ... The company will provide new pneumatic tube systems or expand existing systems within ...
(Date:2/3/2016)... ... 03, 2016 , ... Resilinc released online today ... nearly 750 unique supply chain notifications and alerts generated by its EventWatch ... risk management practitioners subscribe to the EventWatch service to receive early warnings and ...
Breaking Biology Technology: